Status:
COMPLETED
ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
Lead Sponsor:
AstraZeneca
Conditions:
Non Small Cell Lung Cancer
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC on entry into study suitable for pemetrexed therapy
- Patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of adjuvant platinum-based chemotherapy
- Life expectancy of \> 12 weeks
Exclusion
- Prior treatment with pemetrexed in the last 12 months.
- Prior therapy with an ET receptor antagonist
- Any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00745875
Start Date
August 1 2008
End Date
January 1 2010
Last Update
June 6 2012
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
research Site
Pleven, Bulgaria
2
Research Site
Sofia, Bulgaria
3
Research Site
Varna, Bulgaria
4
Research Site
Jičín, Czechia